title: N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperfused Acute Myocardial Infarction.
abstract: The antioxidant N-acetycysteine can turn into a prooxidant molecule in presence of iron ions. Thus, our goal was to test if the association of N-acetylcysteine (NAC) and an iron chelator (deferoxamine--DFX) in a rodent model of acute myocardial infarction (AMI) improves cardiac function. Male Wistar rats were subjected to a SHAM surgery or AMI. The animals were randomized: vehicle, NAC (25 mg/kg for 28 days), DFX (40 mg/kg for 7 days), or NAC plus DFX (NAC plus DFX, respectively). Animals were killed 28 days after the AMI. Animals treated with NAC/DFX showed an increase in left ventricular ejection fraction at 28 days when compared with vehicle group (45.2 ± 10.9 % vs. 34.7 ± 8.7 %, p = 0.03). Antioxidant effect of NAC/DFX treatment decreased 4-hydroxynonenal when compared to AMI group (p = 0.06). In conclusion, we showed beneficial effect of NAC/DFX association in improving left ventricle function in an experimental AMI.
authors.affiliation: Cardiovascular Research Laboratory, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, Porto Alegre, RS, 90035-003, Brazil, a.phpinto@gmail.com.
authors.forename: Amanda
authors.initials: A
authors.lastname: Phaelante
authors.forename: Luís Eduardo
authors.initials: LE
authors.lastname: Rohde
authors.forename: Amanda
authors.initials: A
authors.lastname: Lopes
authors.forename: Virgílio
authors.initials: V
authors.lastname: Olsen
authors.forename: Santiago Alonso Leitão
authors.initials: SA
authors.lastname: Tobar
authors.forename: Carolina
authors.initials: C
authors.lastname: Cohen
authors.forename: Nidiane
authors.initials: N
authors.lastname: Martinelli
authors.forename: Andréia
authors.initials: A
authors.lastname: Biolo
authors.forename: Felipe
authors.initials: F
authors.lastname: Dal-Pizzol
authors.forename: Nadine
authors.initials: N
authors.lastname: Clausell
authors.forename: Michael
authors.initials: M
authors.lastname: Andrades
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage*; D000447:Aldehydes; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage*; D003676:Deferoxamine / Q000008:administration & dosage*; D004452:Echocardiography; D007150:Immunohistochemistry; D007501:Iron / Q000097:blood; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology; D018384:Oxidative Stress / Q000502:physiology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013318:Stroke Volume / Q000502:physiology; D013438:Sulfhydryl Compounds / Q000097:blood; D019210:Troponin I / Q000097:blood; D016276:Ventricular Function / Q000187:drug effects*
chemical_list: D000447:Aldehydes; D000975:Antioxidants; D007502:Iron Chelating Agents; D013438:Sulfhydryl Compounds; D019210:Troponin I; D007501:Iron; D003676:Deferoxamine; C027576:4-hydroxy-2-nonenal; D000111:Acetylcysteine